TH Theratechnologies Inc.

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV

Study Demonstrates Excess Visceral Abdominal Fat Drives CV Risk

MONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today presented data highlighting the limitations of using body mass index (BMI) alone in assessing cardiovascular (CV) risk in people with HIV (PWH). The study underscores the need to incorporate screening for excess visceral abdominal fat (EVAF) to better identify PWH at risk of CV disease.

In a poster presentation at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, Calif., investigators from the Visceral Adiposity Measurement and Observation Study (VAMOS) characterized BMI as a poor independent surrogate for excess visceral adiposity and CV risk in PWH, particularly given the high CV risk observed in study participants with a normal or overweight BMI (“low BMI”) but high levels of EVAF. The investigators that EVAF is one of several risk factors that contribute to heightened CV risk in PWH who are on modern antiretroviral therapy (ART) regimens.

“There is abundant evidence of substantial weight gain and a high prevalence of obesity among people with HIV in the modern antiretroviral era,” commented lead VAMOS investigator Karam C. Mounzer, MD, Chief Scientific Officer at Philadelphia FIGHT Community Health Centers in Philadelphia, Pa. “Clinicians routinely use BMI as a marker to assess the risk of cardiovascular disease and other comorbidities in this population, but often overlook the importance of identifying excess visceral abdominal fat, or EVAF. Our findings not only suggest that relying solely on BMI underestimates cardiovascular risk but show a high prevalence of EVAF among patients with normal BMI which is an actual driver of such risk in people with HIV, that many clinicians fail to capture in their clinics.”

VAMOS is a cross-sectional, multicenter, observational study investigating the relationships between BMI, EVAF (defined as a visceral adipose tissue [VAT] surface area ≥130 cm2), and CV risk factors in 170 PWH who had attained virological suppression on ART for at least one year. The investigators compared 10-year atherosclerotic cardiovascular disease (ASCVD) risk scores across four distinct groups:

  • Low BMI (20-29 kg/m2) without EVAF (VAT <130 cm2) (n=62)
  • Low BMI with EVAF (VAT >130 cm2) (n = 52)
  • High BMI (30-40 kg/m2) without EVAF (n = 10)
  • High BMI with EVAF (n = 46)

Unsurprisingly, obese individuals (BMI 30-34.9 kg/m2) had the highest prevalence of EVAF (88%) in the study, followed by class II obese PWH (BMI 35-40 kg/m2; 69%). However, EVAF was still present in a substantial portion of PWH with normal BMI (20-25 kg/m2; 43%) and those classified as overweight (BMI 25-29.9 kg/m2; 47%).

Notably, PWH with EVAF had higher 10-year ASCVD risk scores than those without EVAF, irrespective of BMI (p=0.0019). Additionally, high levels of pericardial fat volume (PFV, fat within the heart muscle) were found predominantly in participants with high EVAF, compared to those with low EVAF levels (p <0.0001). In a related finding, VAT area was more strongly correlated with PFV (Spearman r value = 0.73; p <0.0001) than with subcutaneous fat area (Spearman r = 0.2; p = 0.0109).

“In addition to providing a predictive estimate of cardiovascular risk, the VAMOS findings show a substantial, real-time impact of fat in the body, as evidenced by the levels of pericardial fat volume,” noted Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies. “The results also underscore that if healthcare providers focus solely on BMI, a sizeable population of normal-weight and overweight individuals with HIV and EVAF will be missed. We hope this study encourages the use of simple and more precise tools for assessing EVAF, such as measuring waist circumference, as a proven means of identifying people with HIV who are at risk of cardiovascular disease.”

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at , on SEDAR+ at  and on EDGAR at . Follow Theratechnologies on  and .

Forward-Looking Information

This press release contains forward-looking statements and forward-looking information (collectively, the “Forward-Looking Statements”), within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as "may", "will", "should", "could", “promising”, “would”, "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the use of tools to measure EVAF, such as waist circumference. Forward-looking statements involve a number of assumptions, risks and uncertainties. Some of these assumptions include, but are not limited to, the fact that healthcare providers will rely on the data and evidence presented for screening for EVAF to better identify PWH at risk of CV disease. The Company refers current and potential investors to the “Risk Factors” section of the Company’s Annual Information Form filed on Form 20-F dated February 26, 2025 available on SEDAR+ at  and on EDGAR at  under Theratechnologies’ public filings for the risks associated with the business of Theratechnologies. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent the Company’s expectations as of that date.

The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Contacts:

Media inquiries:

Julie Schneiderman

Senior Director, Communications & Corporate Affairs



1-514-336-7800

Investor Inquiries:

Joanne Choi

Senior Director, Investor Relations



1-551-261-0401



EN
12/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Theratechnologies Inc.

 PRESS RELEASE

Theratechnologies présente des données de suppression virologique enco...

Theratechnologies présente des données de suppression virologique encourageantes provenant de l’essai PROMISE-US portant sur l’ibalizumab lors de la CROI Les résultats montrent des niveaux semblables de charge virale indétectable chez les patients qui reçoivent des traitements comprenant de l’ibalizumab que chez les témoins, malgré un degré de gravité initial du VIH supérieur L’ibalizumab continue de montrer son efficacité et son innocuité à long terme dans le cadre d’un traitement antirétroviral d’association chez les personnes vivant avec le VIH qui ont déjà reçu de nombreux traitement...

 PRESS RELEASE

Theratechnologies Presents Encouraging Virologic Suppression Data from...

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV Ibalizumab continues to demonstrate long-term efficacy and safety as part of combination antiretroviral therapy in heavily treatment-experienced people with multidrug resistant HIV MONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a...

 PRESS RELEASE

Theratechnologies CROI Presentation Highlights Limitations of Using BM...

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV Study Demonstrates Excess Visceral Abdominal Fat Drives CV Risk MONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today presented data highlighting the limitations of using body mass index (BMI) alone in assessing cardiovascular (CV) risk in people with HIV (PWH). The study underscores the need to incorporate screening for excess viscer...

 PRESS RELEASE

La présentation de Therachnologies lors de la CROI met en évidence les...

La présentation de Therachnologies lors de la CROI met en évidence les limites liées à l’utilisation de l’IMC pour évaluer le risque de maladie cardiovasculaire (CV) chez les personnes vivant avec le VIH Une étude montre que l’excès de graisse viscérale abdominale est associé au risque de maladie CV MONTRÉAL, 12 mars 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade commercial, a présenté aujourd’hui des données mettant en évidence les limites liées à l’utilisation de l’indice de m...

 PRESS RELEASE

Theratechnologies Reports Financial Results for the Fourth Quarter and...

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024 Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 million Achieved record quarterly revenue of $25 million and annual revenue of $85.9 million New credit facilities’ favorable interest rates and amortization schedules free up approximately $19 million in cash in 2025 In-licensed two new Ionis assets in Canada to drive long-term growth MONTREAL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Therat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch